esmolol has been researched along with atenolol in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Ball, JB; Iakovidis, D; Jackman, G; Louis, WJ; Nero, TL; Tung, L | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chang, Q; Chen, Z; Hu, G; Hu, L; Li, Q; Long, J | 1 |
| Fusilli, L; Lee, W; Patel, J; Regan, TJ | 1 |
| Hamm, C; Mitrovic, V; Oehm, E; Pitschner, H; Thormann, J | 1 |
| Anavekar, NS; Drummer, OH; Iakovidis, D; Jackman, GP; Louis, SN; Louis, WJ; Mori, M; Nero, TL; Rezmann-Vitti, LA | 1 |
| Berry, C; Corbett, W; Fleisher, LA; Poldermans, D | 1 |
| Andersson, KK; Barra, AL; Engalytcheff, A; Kolberg, M; Tilquin, B | 1 |
| Andreadou, I; Bofilis, E; Cokkinos, P; Iliodromitis, EK; Kremastinos, DT; Tasouli, A; Zoga, A | 1 |
| Mizogami, M; Takakura, K; Tsuchiya, H | 1 |
| Amin, SM; Amr, YM | 1 |
| Freundlich, RE; Kheterpal, S; Mashour, GA; Matlen, L; Merte, J; Nallamothu, BK; Shanks, A; Sharifpour, M; Tremper, KK; Vlisides, PE; Weightman, A | 1 |
| Cafferkey, A; McMahon, C | 1 |
| Addison, D; Alam, M; Jneid, H; Kayani, W; Lakkis, N; Misra, A; Pham, D; Resar, J | 1 |
2 review(s) available for esmolol and atenolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Outcomes of beta blocker use in cocaine-associated chest pain: a meta-analysis.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Carvedilol; Cocaine; Humans; Metoprolol; Propanolamines; Propranolol | 2018 |
2 trial(s) available for esmolol and atenolol
| Article | Year |
|---|---|
Potassium channel openers and blockers in coronary artery disease. Comparison to betablockers and calcium antagonists.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Angina Pectoris; Anti-Arrhythmia Agents; Atenolol; Benzopyrans; Bridged Bicyclo Compounds, Heterocyclic; Calcium Channel Blockers; Cardiotonic Agents; Coronary Disease; Cyclopropanes; Dihydropyridines; Electrocardiography; Exercise Test; Gallopamil; Hemodynamics; Humans; Middle Aged; Myocardium; Oxygen Consumption; Potassium Channel Blockers; Potassium Channels; Propanolamines; Time Factors; Vasodilator Agents | 2000 |
Effects of preoperative oral beta blocker versus intraoperative nitroprusside or esmolol on quality of surgical field during tympanoplasty.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Adult; Atenolol; Blood Pressure; Double-Blind Method; Female; Heart Rate; Hospitals, University; Humans; Hypertension; Infusions, Intravenous; Intraoperative Care; Male; Middle Aged; Nitroprusside; Preoperative Care; Propanolamines; Tympanoplasty; Vasodilator Agents | 2011 |
14 other study(ies) available for esmolol and atenolol
| Article | Year |
|---|---|
Computer-aided mapping of the beta-adrenoceptor. 1. Explanation for effect of para substitution on blocking activity at the beta-1-adrenoceptor.
Topics: Adrenergic beta-Antagonists; Computer Simulation; Propanolamines; Stereoisomerism; Structure-Activity Relationship | 1992 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Repositioning; Drug Screening Assays, Antitumor; Humans; Melanoma; Molecular Docking Simulation; Molecular Structure; Propanols; Skin Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Anti-arrhythmic efficacy of beta-adrenergic blockade during acute ischemia in myocardium with scar.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Disease Models, Animal; Dogs; Heart Rate; Male; Myocardial Infarction; Myocardial Ischemia; Propanolamines; Ventricular Fibrillation | 1994 |
Synthesis, beta-adrenoceptor pharmacology and toxicology of S-(-)-1-(4-(2-ethoxyethoxy)phenoxy)-2-hydroxy-3-(2-(3,4-dimethoxyphenyl)ethylamino)propane hydrochloride, a short acting beta(1)-specific antagonist.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Atenolol; Chromatography, High Pressure Liquid; Dogs; Female; Half-Life; Heart Atria; In Vitro Techniques; Infusions, Intravenous; Magnetic Resonance Spectroscopy; Myocardial Contraction; Propane; Propanolamines; Rats; Rats, Sprague-Dawley; Trachea | 2002 |
Cost-effectiveness of differing perioperative beta-blockade strategies in vascular surgery patients.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aortic Aneurysm, Abdominal; Atenolol; Bisoprolol; Cost-Benefit Analysis; Decision Support Techniques; Humans; Infusions, Intravenous; Metoprolol; Perioperative Care; Postoperative Complications; Propanolamines; Treatment Outcome; Vascular Surgical Procedures | 2004 |
The use of multi-frequency EPR techniques to identify the radicals produced in irradiated beta-blockers.
Topics: Adrenergic beta-Antagonists; Atenolol; Electron Spin Resonance Spectroscopy; Free Radicals; Nadolol; Propanolamines; Propranolol; Temperature | 2004 |
Intravenous atenolol and esmolol maintain the protective effect of ischemic preconditioning in vivo.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Hemodynamics; Infusions, Intravenous; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Propanolamines; Rabbits; Survival Rate; Time Factors | 2004 |
The interactivities with lipid membranes differentially characterize selective and nonselective beta1-blockers.
Topics: Adrenergic beta-Antagonists; Alprenolol; Anesthesia; Anesthetics; Atenolol; Biomimetics; Lipid Bilayers; Lipids; Liposomes; Membranes, Artificial; Metoprolol; Oxprenolol; Propanolamines; Propranolol; Receptors, Adrenergic, beta | 2010 |
Perioperative metoprolol and risk of stroke after noncardiac surgery.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Analysis of Variance; Atenolol; Cohort Studies; Data Interpretation, Statistical; Female; Humans; Incidence; Labetalol; Logistic Models; Male; Metoprolol; Middle Aged; Monitoring, Intraoperative; Odds Ratio; Postoperative Complications; Propanolamines; Retrospective Studies; Risk Factors; Stroke; Treatment Outcome; Young Adult | 2013 |
Successful Treatment of Refractory Cardiac Arrest With β-Blockade and Extracorporeal Life Support in a Pediatric Patient With Catecholaminergic Polymorphic Ventricular Tachycardia: A Case Report.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atenolol; Calcium-Binding Proteins; Child; Combined Modality Therapy; Defibrillators, Implantable; Electrocardiography; Extracorporeal Membrane Oxygenation; Heart Arrest; Humans; Male; Membrane Proteins; Muscle Proteins; Mutation; Propanolamines; Propranolol; Sympathectomy; Tachycardia, Ventricular | 2018 |